GlassScriptPhysician profile
Patricia Anthony
NPI 1871371310
$2,058.77
in general payments reported to CMS, 2019-2025
23 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.86 · 2023: $344 · 2024: $540 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $760.53 | 2023-2025 | Optune, Optune Gio, Optune Lua (Novottf-200t) |
| Telix Pharmaceuticals | $456.23 | 2025 | Illuccix |
| Grifols USA, LLC | $119.05 | 2025 | Gamunex-C |
| E.R. Squibb & Sons, L.L.C. | $103.83 | 2024 | Zeposia |
| Servier Pharmaceuticals LLC | $87.16 | 2024-2025 | |
| Argenx US, INC. | $81.77 | 2025 | Vyvgart Hytrulo |
| Ucb, INC. | $79.45 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Lilly USA, LLC | $61.27 | 2021-2024 | Reyvow, Emgality |
| Biogen, INC. | $50.61 | 2023-2024 | Vumerity |
| Abbvie INC. | $32.96 | 2025 | |
| Hologic Sales and Service, LLC | $28.03 | 2025 | Fluent Fluid Management System, Myosure Tissue Removal Device |
| Novo Nordisk INC | $20.91 | 2023 | Wegovy |
| Alexion Pharmaceuticals, INC. | $18.78 | 2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $18.06 | 2024 | Libtayo |
| Springworks Therapeutics, INC. | $17.17 | 2025 | Gomekli |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $17.05 | 2025 | |
| Immedica Pharma US, INC. | $16.67 | 2024 | |
| Neurelis, INC. | $16.35 | 2025 | Valtoco |
| Sk Life Science, INC. | $15.61 | 2025 | |
| Tonix Medicines, INC. | $15.06 | 2025 | Zembrace Symtouch |
| Astrazeneca Pharmaceuticals LP | $14.57 | 2025 | |
| Vanda Pharmaceuticals INC. | $13.90 | 2025 | Ponvory |
| Azurity Pharmaceuticals, INC. | $13.75 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.